Mental health disorders according to DSM-5, as measured by the Short Interview for Mental Disorders (Mini-DIPS
Conditions
Interventions
Group 1: Study participants will be divided into two groups. One group (n = 40) will receive MeMoPsy which contains basic modules for building a supportive therapeutic alliance and helping patients to
McCullough et al., 2015), Dialectic Behavioral Therapy (DBT
Linehan, 1996) und Solution Focused Brief Therapy (SFBT
Bavelas et al., 2013).
The MeMoPsy intervention consists of 28 individual therapy sessions. The first 8 sessions will occur twice a week over the course of one month. The remaining 20 sessions will
Sponsors
DZPG (Deutsches Zentrum für Psychische Gesundheit)
Eligibility
Sex/Gender
All
Age
15 Years to 25 Years
Inclusion criteria
Inclusion criteria: • At least one diagnosis of a mental health disorder according to the DSM-5, as assessed by means of Mini-DIPS (Magraf & Cwik, 2017; for exceptions see exclusion criteria), the Structured Clinical Interview (SCID-5-CV, only the subset of questions dealing with ADHS, Beesdo-Baum, K., Zaudig, M., & Wittchen, H.-U., 2019), and the Structured Clinical Interview for Personality Disorders (SCID-5-PD, Beesdo-Baum, K., Zaudig, M., & Wittchen, H.-U., 2019) • At least 1 cut-off of the following measures is exceeded: 1) Rejection Sensitivity Questionnaire (RSQ = 9.88), 2) State Difficulties in Emotion Regulation Scale (S-DERS = 46.97), or 3) “Interpersonal Relationships” subscale of the Outcome Questionnaire-45 (EB-45 = 13) • Traumatic experiences in childhood and/or adolescence: moderate to severe scores on one of the subscales of the Childhood Trauma Questionnaire (CTQ; Klinitzke et al., 2012) according to Häuser and colleagues (2011) • Fluent in German • Health insurance
Exclusion criteria
Exclusion criteria: - Posttraumatic stress disorder, as assessed with Mini-DIPS (Margraf & Cwik, 2017) - moderate or severe substance abuse disorder (exception: cannabis), as assessed with Mini-DIPS (Margraf & Cwik, 2017) - currently suffering from acute psychotic symptoms, as assessed with Mini-DIPS (Margraf & Cwik, 2017) - currently suffering from acute manic symptoms, as assessed with Mini-DIPS (Margraf & Cwik, 2017) - Autism spectrum disorder, as assessed with the short version of the Autism spectrum quotient questionnaire (AQ-10; Allison et al., 2012) - currently participating in another psychotherapy - severe cognitive impairment (IQ 6 dioptres and no contact lenses
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acceptance of the intervention: -Patient satisfaction: Fragebogen zur Patientenzufriedenheit (ZUF-8; Schmidt et al., 1989; end of therapy, T2) -Therapist satisfaction: Acceptability of Intervention Measure and Feasibility of Intervention Measure (AIM; Weiner et al., 2017; end of therapy, T2) -Potential negative effects: through study patients with Negative Effects Questionnaire (NEQ; Rozental et al., 2019) reported (end of therapy, T2) -Adherence: Study dropout and number of therapy sessions used -Reasons for therapy dropout: Reasons for Terminating Therapy Scale (RTTS; Roe et al., 2006) Feasibility: - Speed of recruitment and recruitment rate - Completeness of assessments - Study dropout - Quality of module-specific cut-off values Assessment of intervention effects and working mechanisms of MeMoPsy: -Self-report for symptom severity: Brief Symptom Inventory (BSI; Franke, 2000; end of therapy, T2) -Clinically rated symptom severity: Therapists assess Global Assessment of Functioning (GAF; American Psychiatric Association, 1987) and Global Assessment of Relational Functioning (GARF) every 5th session; the diagnostics team (blind) assesses GAF at T0 and T2 | — |
Secondary
| Measure | Time frame |
|---|---|
| Differences with regard to working mechanisms of MeMoPsy and CBT will be assessed using the following self-report questionnaires: Expected psychobiological mechanisms of change: - Rejection sensitivity: Rejection Sensitivity Questionnaire (RSQ; Downey & Feldman, 1996; T1, T2 und T3) - Emotion dysregulation: State Difficulties in Emotion Regulation Scale (S-DERS; Lavender et al., 2017; T1, T2 und T3) - Social relationships: Ergebnisfragebogen-45, subscale „Zwischenmenschliche Beziehungen“ (EB-45; Haug et al., 2004; T1, T2 und T3) Changes in symptom severity and working alliance at T1, T2 and T3 - Severity of personality disorder: German, modified short version of the Personality Inventory for DSM-5 (PID-5-BF+M, Bach et al., 2020) and the German version of Level of Personality Functioning Scale-Brief Form 2.0 (LPFS-BF, Spitzer et al. 2021) - Severity of borderline personality disorder: Fragebogen zu Gedanken und Gefühlen (FGG; Renneberg et al., 2010) and 23-item version of the Borderline Symptom Liste (BSL-23; Bohus et al., 2009) - Social support: ENRICHD Social Support Inventory (ESSI; Cordes et al., 2009) - Mentalizing capacity: Certainty about Mental State Questionnaire (CAMSQ; Müller et al., 2021) - Dissociation: 4-Item-Version of the Dissoziations-Spannungs-Skala (Stiglmayr et al., 2009). - Overall clinical impression (Schweregrad, Verbesserung): Clinical Global Impression (Guy, 1976; T1 und T2) - DZPG Minimum Data Set which contains general questions about physical and mental health during the course of the therapy - Medication - Psychotherapeutic processes: Therapeutic homework and therapeutic interventions (self-designed Therapeutic Elements Checklist) - Working alliance: Working Alliance Inventory – Short Revised (WAI-SR; Munder et al., 2010); patient and therapist at T1 and T2 Therapeutic processes in the MeMoPsy group: - Content of therapy session: Stundenbogen für die allgemeine und differentielle Einzelpsychotherapie (STEP; Kra | — |
Countries
Germany
Contacts
Public ContactKatja Seitz
Klinik für Allgemeine Psychiatrie
Outcome results
None listed